Head to Head Contrast: Phio Pharmaceuticals (NASDAQ:PHIO) and Shineco (NASDAQ:SISI)

Phio Pharmaceuticals (NASDAQ:PHIO) and Shineco (NASDAQ:SISI) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, risk, dividends, earnings and valuation.

Volatility and Risk

Phio Pharmaceuticals has a beta of 0.9, indicating that its stock price is 10% less volatile than the S&P 500. Comparatively, Shineco has a beta of -1.33, indicating that its stock price is 233% less volatile than the S&P 500.

Valuation and Earnings

This table compares Phio Pharmaceuticals and Shineco”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Phio Pharmaceuticals	N/A	N/A	-$8.70 million	($1.45)	-0.87
Shineco	$9.60 million	0.01	-$22.45 million	($204.00)	0.00

Phio Pharmaceuticals has higher earnings, but lower revenue than Shineco. Phio Pharmaceuticals is trading at a lower price-to-earnings ratio than Shineco, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings and target prices for Phio Pharmaceuticals and Shineco, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Phio Pharmaceuticals	1	0	1	0	2.00
Shineco	1	0	0	0	1.00

Phio Pharmaceuticals currently has a consensus price target of $14.00, indicating a potential upside of 1,011.11%. Given Phio Pharmaceuticals’ stronger consensus rating and higher probable upside, equities research analysts clearly believe Phio Pharmaceuticals is more favorable than Shineco.

Profitability

This table compares Phio Pharmaceuticals and Shineco’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Phio Pharmaceuticals	N/A	-66.59%	-60.26%
Shineco	-380.55%	-79.89%	-33.01%

Insider & Institutional Ownership

57.3% of Phio Pharmaceuticals shares are held by institutional investors. Comparatively, 4.1% of Shineco shares are held by institutional investors. 0.9% of Phio Pharmaceuticals shares are held by company insiders. Comparatively, 0.0% of Shineco shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Phio Pharmaceuticals beats Shineco on 10 of the 13 factors compared between the two stocks.

About Phio Pharmaceuticals

Phio Pharmaceuticals Corp. engages in the development of immuno-oncology therapeutics in the United States. The company is developing PH-762, an INTASYL compound in Phase 1b dose-escalating clinical trials to reduce the expression of cell death protein 1 (PD-1), a protein that inhibits T cells’ ability to kill cancer cells; and PH-762 treated double positive tumor infiltrating lymphocytes, which is in Phase 1 clinical trials to treat advanced melanoma and other advanced solid tumors. It is also developing PH-894, an INTASYL compound in IND enabling studies to silence BRD4, a protein that controls gene expression in both T cells and tumor cells, effecting the immune system and the tumor. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is based in Marlborough, Massachusetts.

About Shineco

Shineco, Inc., through its subsidiaries, processes and distributes agricultural produce. It also engages in the growing and cultivation of mulberry trees and silkworm cocoons; distribution of fruit business; and processing and distribution of silk and silk fabrics, as well as other by-products. The company was incorporated in 1997 and is headquartered in Beijing, the People's Republic of China.